Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio
Positioned As ‘Off-The-Shelf’ Rival To CAR-Ts
Lunsumio and the late-stage glofitamab will complement antibody drug conjugate Polivy in Roche's hemato-oncology portfolio. • Source: Shutterstock 
